Comparison · NCT02394730-84aa43ee
Vorapaxar vs Placebo: Total Number of Participants With Any SAE Between Baseline and Week 18
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vorapaxar vs Placebo: Total Number of Participants With Any SAE Between Baseline and Week 18. Trial comparisons, record NCT02394730-84aa43ee. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02394730-84aa43ee
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0314 | 0.236 | wilson | |
| Risk in group 2 | 0.0645 | 0.0179 | 0.207 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0264 | -0.128 | 0.179 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.252 | 7.87 | log | |
| Odds ratio, group 1 over group 2 | 1.45 | 0.226 | 9.32 | log | |
| Number needed to treat, for one more participant with the outcome on Vorapaxar than on Placebo | 37.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vorapaxar | 2.5mg of vorapaxar po qd~vorapaxar: 2.5mg of vorapaxar taken orally once daily for 12 weeks | 3 | 33 | OG000 |
| Group 2 | Placebo | sugar pill po qd~Placebo: Sugar pill taken orally once daily for 12 weeks | 2 | 31 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Total Number of Participants With Any SAE Between Baseline and Week 18
- Description
- Total number of participants with any SAE between baseline and week 18
- Time frame
- week 18
- Population
Source ClinicalTrials.gov
Trial
- Title
- Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints
- NCT number
- NCT02394730
- Phases
- PHASE1, PHASE2
- Conditions
- HIV
- Interventions
- vorapaxar, Placebo
- Lead sponsor
- Kirby Institute
- Results first posted
- 2019-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02394730?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02394730-84aa43ee